BP
Biomarin Pharmaceutical Inc
🇺🇸XNAS.BMRNUnited StatesHealthcare
$64.95USDup +0.51 (+0.79%)OpenDelayed5:49 PM
Price$64.95+0.51 (+0.79%)
Profile
- Healthcare
- Biotechnology
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- US09061G1013
- CUSIP
- 09061G101
Company
- Employees
- 3,221
- Headquarters
- San Rafael, United States
- Website
- https://www.biomarin.com
- CEO
- Mr. Alexander Hardy
Market
- Shares outstanding
- 193.6M
- Market cap
- $12.57B
Key dates
- Next earnings
- Oct 26, 2026
Highlights
- Market cap
- $12.47B
- EPS LTM
- $0.38
- P/E LTM
- 152.24
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $3.41B+11.2%up year on year
- Net income
- $72.97M-88.9%down year on year
- Gross margin
- 75.55%-5.04%down year on year
- Free cash flow
- $732.88M+5.99%up year on year
Other listings
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.